AI-generated summary
This critical review examined photobiomodulation as a possible adjunct for asthma, drawing on preclinical and clinical literature searched through April 2026. The authors report that in most experimental asthma models, certain light doses reduced Type 2 inflammatory cytokines and eosinophil recruitment, and that some clinical studies showed reduced symptoms and exacerbations. The authors describe the approach as potentially affordable and relatively safe, but call for carefully designed clinical trials.
- Who or what was studied
- unclear
- Limits stated in the abstract
- The abstract states that dosimetry, irradiation geometry, tissue optics and delivery of light to intrathoracic airways remain underdeveloped, and that evidence is largely preclinical and requires further trials.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Total energy
- 3J, 5J
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Near-infrared, Inflammation, Dosimetry, Collagen, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.